 |
|
BioControl secures £500,000
BioControl, a UK-based company developing a phage-based treatment for pseudomonas aeruginosa infections, has raised £500,000 in its first institutional round.
This comprised £250,000 from The Capital Fund and £250,000 from existing shareholders.
Pseudomonas is highly resistant to antibiotics; infections are persistent and can be lethal. Pseudomonas is a particular threat to cystic fibrosis sufferers. Biocontrol’s phage therapy has proved effective in phase two trials for topical applications. Biocontrol is now targeting the deep lung.
Patrick Benham-Crosswell of BC Capital, BioControl’s corporate finance adviser, said: “This investment enables BioControl to develop its therapy in preparation for wider trials. As the extent of pseudomonas infections becomes known, demand for Biocontrol’s phage-based therapies is likely to rise.”
People also read ... |
Related Articles |
Interesting links
Other Sector Watch
- Crisis?– what crisis? Jul 01 2008
- A double whammy Jun 12 2008
- Let the
drilling begin
May 13 2008 - Bargains on the high street
Mar 13 2008 - Sowing the seed Mar 03 2008
M&A News
- Gooch & Housego buys
US firm Jul 04 2008 - Franking machine business'
£1m boost Jul 03 2008 - Ingenious to continue
investment spree Jul 03 2008 - LDC backs Eve Trakway Jul 02 2008
- Nomads expect AIM
slowdown to continue Jul 02 2008
Special Offers
- 2008 AIM Guide: Jul 17 2007
- Growth Company Investor Magazine: Jul 17 2007
- Cash Shells 2007 - Research report Jul 17 2007
- Venture Capital Trusts Jul 04 2007
M&A Deals
- Bets are off for William Hill Jul 02 2008
- Stobart’s cool head for business Jul 01 2008
- Smiths heads Down Under Jul 01 2008
- Maxima agrees DXI deal Jun 30 2008
- Candover bulks up with gym deal Jun 30 2008